search
Back to results

Severe OSA Study (SOS)

Primary Purpose

Obstructive Sleep Apnea, Sleep Apnea

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ProSomnus® EVO Sleep and Snore Device
Sponsored by
ProSomnus Sleep Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obstructive Sleep Apnea focused on measuring oral appliance, mandibular advancement device

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Provision of signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, of any race, aged 18-80 years (inclusive)
  4. Diagnosed with uncomplicated severe OSA (i.e., AHI > 30 h-1); where uncomplicated is defined by the absence of:

    1. Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation, and sleep-related hypoxemia). Examples of such conditions include significant cardiopulmonary disease, potential respiratory muscles weakness due to neuromuscular conditions, history of stroke, and chronic opiate medication use.
    2. Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep-related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia).
    3. Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT.
  5. Body mass index (BMI) < 45 kg/m2
  6. Neck circumference < 50 cm
  7. Absence of severe oxyhemoglobin desaturation during sleep, indicated by mean nocturnal SpO2 > 87%
  8. Mandibular range of motion > 5 mm in protrusive direction
  9. Adequate dentition, as determined by the site dentist

Exclusion Criteria:

  1. Inability to breathe through the nose comfortably
  2. Presence of > 25% CSA
  3. Presence of positional obstructive sleep apnea per Cartwright's definition32
  4. History of surgery intended to alter anatomy for the correction of OSA, such as uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), or tongue/hyoid suspension. History of surgery intended to restore normal anatomy, such as tonsillectomy, adenoidectomy, septoplasty, or polypectomy, is permitted
  5. Presence of hypoglossal nerve stimulation device
  6. Use of CPAP or OAT within the two weeks prior to the screening HSAT
  7. History of OAT that has been demonstrated to provide effective therapy within the two years prior to the screening HSAT
  8. Anticipated change in medical therapy during the study protocol that could alter OSA severity (e.g., weight loss surgeries; UPPP, MMA, tongue/hyoid suspension)
  9. Loose teeth or advanced periodontal disease
  10. History of temporomandibular joint disorder
  11. Resistant hypertension, defined as inadequately controlled blood pressure despite therapy with ≥ 3 oral hypertensive agents
  12. Presence of congestive heart failure, recurrent atrial fibrillation, or coronary artery disease
  13. Presence of neuromuscular diseases, hypoventilation disorders, or cerebrovascular disease
  14. Presence of pulmonary disease resulting in significant desaturation, e.g., severe chronic obstructive pulmonary disease, interstitial lung disease (SaO2 nadir of 87%), or pulmonary hypertension
  15. History of cerebrovascular incident within the last 12 months
  16. Use of pacemaker or other life supporting device
  17. Anticipated change in body weight > 5% during the study period
  18. Participation in other studies that could interfere with the study protocol
  19. Pregnancy or lactation
  20. In the opinion of the investigator, unsuitable for inclusion in the study

Sites / Locations

  • Stanford Sleep Medicine ClinicRecruiting
  • Brigham and Women's HospitalRecruiting
  • University of MinnesotaRecruiting
  • Advanced ENT Physicians and Surgeons of CNY
  • Mount Sinai Integrative Sleep CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EVO Sleep and Snore Device

Arm Description

Participants will be provided with a custom EVO Sleep and Snore Device

Outcomes

Primary Outcome Measures

Efficacy (apnea-hypopnea index)
The AHI co-primary effectiveness endpoint is to demonstrate a responder rate significantly greater than 50%; responders will be defined as individuals who achieve an AHI < 15 h-1 with the EVO Sleep and Snore Device 6 months after initiation of the therapy.
Efficacy (oxygen desaturation index)
The ODI co-primary effectiveness endpoint is to demonstrate a responder rate significantly greater than 50%; responders will be defined as individuals who achieve decrease in ODI from baseline of 25% or more with the EVO Sleep and Snore Device 6 months after initiation of the therapy.
Evaluation of safety (adverse events, dental examinations, safety examinations)
The primary safety endpoint is to demonstrate an acceptable safety profile of the EVO Sleep and Snore Device, determined through assessment of all reported adverse events, dental examinations, and safety evaluations. There will be no formal statistical analysis.

Secondary Outcome Measures

Epworth Sleepiness Scale
The secondary endpoint is to demonstrate that the minimum clinically important difference (MCID) of -2 on the Epworth Sleepiness Scale (ESS) is achieved in participants with moderate to excessive daytime sleepiness (defined as ESS > 12). The Epworth Sleepiness Scale is a scale that ranges from 0 (no daytime sleepiness) to 18 (excessive daytime sleepiness).

Full Information

First Posted
June 30, 2022
Last Updated
September 7, 2023
Sponsor
ProSomnus Sleep Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT05445869
Brief Title
Severe OSA Study (SOS)
Official Title
A Prospective, Multi-Center, Single-Arm, Open-Label, Observational Study on the Safety and Effectiveness of the ProSomnus EVO Sleep and Snore Device in the Treatment of Severe Obstructive Sleep Apnea
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 12, 2022 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ProSomnus Sleep Technologies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a prospective, multi-center, single-arm, open-label study evaluating the safety and effectiveness of therapy with the ProSomnus EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea.
Detailed Description
This study is a prospective, multi-center, single-arm, open-label study evaluating the safety and effectiveness of therapy with the ProSomnus EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea (OSA). Study participants will receive a custom ProSomnus EVO Sleep and Snore device and then be tested using a Type II home sleep apnea test (HSAT) to determine if they have achieved apnea-hypopnea index (AHI) < 15 h-1 with the device in place. Home sleep apnea testing will be conducted at predetermined timepoints rather than based on subjective measures such as symptom alleviation. After completing a set device advancement and testing protocol, study participants will complete a final HSAT six months after therapy initiation. This value will be used to determine the therapeutic success rate of the appliance. Safety evaluations will be conducted at each study visit that takes place after therapy initiation. These evaluations, along with dental examinations and adverse event reports, will be used to determine if the safety endpoint is met. Participants will continue to be followed for an additional six months after collection of data for the primary endpoints.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea, Sleep Apnea
Keywords
oral appliance, mandibular advancement device

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
EVO Sleep and Snore Device
Arm Type
Experimental
Arm Description
Participants will be provided with a custom EVO Sleep and Snore Device
Intervention Type
Device
Intervention Name(s)
ProSomnus® EVO Sleep and Snore Device
Intervention Description
The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
Primary Outcome Measure Information:
Title
Efficacy (apnea-hypopnea index)
Description
The AHI co-primary effectiveness endpoint is to demonstrate a responder rate significantly greater than 50%; responders will be defined as individuals who achieve an AHI < 15 h-1 with the EVO Sleep and Snore Device 6 months after initiation of the therapy.
Time Frame
6 months
Title
Efficacy (oxygen desaturation index)
Description
The ODI co-primary effectiveness endpoint is to demonstrate a responder rate significantly greater than 50%; responders will be defined as individuals who achieve decrease in ODI from baseline of 25% or more with the EVO Sleep and Snore Device 6 months after initiation of the therapy.
Time Frame
6 months
Title
Evaluation of safety (adverse events, dental examinations, safety examinations)
Description
The primary safety endpoint is to demonstrate an acceptable safety profile of the EVO Sleep and Snore Device, determined through assessment of all reported adverse events, dental examinations, and safety evaluations. There will be no formal statistical analysis.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Epworth Sleepiness Scale
Description
The secondary endpoint is to demonstrate that the minimum clinically important difference (MCID) of -2 on the Epworth Sleepiness Scale (ESS) is achieved in participants with moderate to excessive daytime sleepiness (defined as ESS > 12). The Epworth Sleepiness Scale is a scale that ranges from 0 (no daytime sleepiness) to 18 (excessive daytime sleepiness).
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Male or female, of any race, aged 18-80 years (inclusive) Diagnosed with uncomplicated severe OSA (i.e., AHI > 30 h-1); where uncomplicated is defined by the absence of: Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation, and sleep-related hypoxemia). Examples of such conditions include significant cardiopulmonary disease, potential respiratory muscles weakness due to neuromuscular conditions, history of stroke, and chronic opiate medication use. Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep-related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia). Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT. Body mass index (BMI) < 40 kg/m2 Neck circumference < 50 cm Absence of severe oxyhemoglobin desaturation during sleep, indicated by mean nocturnal SpO2 > 87% Mandibular range of motion > 5 mm in protrusive direction Adequate dentition, as determined by the site dentist Exclusion Criteria: Inability to breathe through the nose comfortably Presence of > 25% CSA Presence of positional obstructive sleep apnea per Cartwright's definition32 History of surgery intended to alter anatomy for the correction of OSA, such as uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), or tongue/hyoid suspension. History of surgery intended to restore normal anatomy, such as tonsillectomy, adenoidectomy, septoplasty, or polypectomy, is permitted Presence of hypoglossal nerve stimulation device Use of CPAP or OAT within the two weeks prior to the screening HSAT History of OAT that has been demonstrated to provide effective therapy within the two years prior to the screening HSAT Anticipated change in medical therapy during the study protocol that could alter OSA severity (e.g., weight loss surgeries; UPPP, MMA, tongue/hyoid suspension) Loose teeth or advanced periodontal disease History of temporomandibular joint disorder Resistant hypertension, defined as inadequately controlled blood pressure despite therapy with ≥ 3 oral hypertensive agents Presence of congestive heart failure, recurrent atrial fibrillation, or coronary artery disease Presence of neuromuscular diseases, hypoventilation disorders, or cerebrovascular disease Presence of pulmonary disease resulting in significant desaturation, e.g., severe chronic obstructive pulmonary disease, interstitial lung disease (SaO2 nadir of 87%), or pulmonary hypertension History of cerebrovascular incident within the last 12 months Use of pacemaker or other life supporting device Anticipated change in body weight > 5% during the study period Participation in other studies that could interfere with the study protocol Pregnancy or lactation In the opinion of the investigator, unsuitable for inclusion in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Director, Medical Affairs
Phone
844 537 5337
Email
info@prosomnus.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erin Mosca, PhD
Organizational Affiliation
ProSomnus Sleep Technologies
Official's Role
Study Director
Facility Information:
Facility Name
Stanford Sleep Medicine Clinic
City
Redwood City
State/Province
California
ZIP/Postal Code
94063
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neehar Thumaty
Email
neehart@standford.edu
First Name & Middle Initial & Last Name & Degree
Clete Kushida, MD, PhD
First Name & Middle Initial & Last Name & Degree
Audrey Yoon, DDS
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Calianese
Phone
617-732-8977
Email
ncalianese@partners.org
First Name & Middle Initial & Last Name & Degree
Ludovico Messineo, MD, PhD
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bri Schimelpfenig
Phone
612-626-8689
Email
schim225@umn.edu
First Name & Middle Initial & Last Name & Degree
Bimaje Akpa, MBBS
First Name & Middle Initial & Last Name & Degree
Jon Parker, DDS
Facility Name
Advanced ENT Physicians and Surgeons of CNY
City
Fayetteville
State/Province
New York
ZIP/Postal Code
13066
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Mount Sinai Integrative Sleep Center
City
New York
State/Province
New York
ZIP/Postal Code
10010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kaveh Gaynor-Sodeifi
Phone
917-471-1682
Email
kaveh.gaynor-sodeifi@mssm.edu
First Name & Middle Initial & Last Name & Degree
David Rapoport, MD
First Name & Middle Initial & Last Name & Degree
David Binder, DDS
First Name & Middle Initial & Last Name & Degree
Thomas Tolbert, MD

12. IPD Sharing Statement

Learn more about this trial

Severe OSA Study (SOS)

We'll reach out to this number within 24 hrs